BioCentury
ARTICLE | Company News

GenVec, National Institutes of Health deal

February 28, 2000 8:00 AM UTC

GenVec received exclusive rights to the pigment epithelium derived factor (PEDF) gene from NIH for use in treating blindness. The company said PEDF is an antiangiogenic factor that could potentially ...